Steve Weinstein

Steve Weinstein brings over 25 years of experience as a CEO, entrepreneur, and venture capitalist across biotech, medical devices, and digital health, working with companies from company formation through R&D, clinical, regulatory, and commercial launch.

As Managing Director of the Novartis Venture Fund for twelve years, he was actively engaged in all investment decisions across the $800M global portfolio and led the Medtech practice.  Prior to Novartis, Steve was on the life science team at Prism Venture Partners, a $1.25B family of funds. He began his venture career as a Kauffman Fellow with Mid-Atlantic Venture Funds.

Steve was the CEO of three start-ups in the diagnostic, medical device, and industrial sectors.

Steve has consulted to Genentech Neuroscience Innovation evaluating novel approaches to treating neurological diseases including neuromuscular, precision psychiatry, and drug delivery.  He is an advisor to the American Academy of Ophthalmology, a member of Product Development Review Council for the Cancer Prevention and Research Institute of Texas (CPRIT), an advisor to the Rockefeller Neuroscience Institute, a member of the Virginia Venture Partners Investment Advisory Board, prior Chairman of SpectraWAVE Inc (cardiovascular imaging), and served on the Innovation Advisory Board of Mass General Brigham Healthcare (2013-2018).

‍